Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any atrial heart septal defect in which the cause of the disease is a mutation in the CITED2 gene.
Features include always present findings: Atrial septal defect; and common findings: Anomalous pulmonary venous return.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 1 | Anomalous pulmonary venous return |
Heart and blood vessels |
CITED2 encodes Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 (270 aa). Transcriptional coactivator of the p300/CBP-mediated transcription complex. Highest expression in Cells Cultured fibroblasts (492.1 TPM) and Ovary (360.7 TPM).
Atrial septal defect 8 is associated with mutations in the CITED2 gene on chromosome 6.
The CITED2 protein participates in CITED2 gene expression is stimulated by FOXO1,FOXO3, FOXO1,FOXO3 bind CITED2 gene promoter, and FOXO1,FOXO3:CITED2 gene pathways.
CITED2 is classified as a druggable target (Transcription Factor category) with score 0.0.
Genetic testing for CITED2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for atrial septal defect 8 has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 1 common feature.
No clinical trials have been registered for atrial septal defect 8.
220 publications have been identified in PubMed for atrial septal defect 8. Kisho has analyzed 156 by research type. Research spans Clinical Trial Publication (32%), Epidemiology / Natural History (26%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 50 | 32% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:52 PM UTC
Online Mendelian Inheritance in Man
1 |
Atrial septal defect |
Disease patterns and progression
41 |
26% |
Research summaries | 23 | 15% |
Patient case studies | 17 | 11% |
Testing and diagnosis research | 15 | 10% |
Laboratory research | 9 | 6% |
Other research | 1 | 1% |
Tartaglia F (2026). [PMID: 42074976](https://pubmed.ncbi.nlm.nih.gov/42074976/). *J Clin Med*. [Review / Meta-Analysis]
Lillitos P (2026). [PMID: 40663135](https://pubmed.ncbi.nlm.nih.gov/40663135/). *Pediatr Cardiol*. [Epidemiology / Natural History]
Raimoglou D (2026). [PMID: 41674134](https://pubmed.ncbi.nlm.nih.gov/41674134/). *Echocardiography*. [Diagnostic / Biomarker]
Noda S (2026). [PMID: 41061875](https://pubmed.ncbi.nlm.nih.gov/41061875/). *Am J Cardiol*. [Clinical Trial Publication]
Chaudhry HS (2026). [PMID: 42083671](https://pubmed.ncbi.nlm.nih.gov/42083671/). *Cureus*. [Epidemiology / Natural History]
Dannesbo S (2026). [PMID: 41242618](https://pubmed.ncbi.nlm.nih.gov/41242618/). *J Am Soc Echocardiogr*. [Epidemiology / Natural History]
Griffith GJ (2026). [PMID: 41634884](https://pubmed.ncbi.nlm.nih.gov/41634884/). *Cardiol Young*. [Clinical Trial Publication]
Balci M (2026). [PMID: 41914268](https://pubmed.ncbi.nlm.nih.gov/41914268/). *Cardiol Young*. [Basic Science / Preclinical]
Still SA (2026). [PMID: 40349944](https://pubmed.ncbi.nlm.nih.gov/40349944/). *Ann Thorac Surg*. [Case Report / Case Series]
Kucera JA (2026). [PMID: 41353025](https://pubmed.ncbi.nlm.nih.gov/41353025/). *J Cardiothorac Vasc Anesth*. [Epidemiology / Natural History]